The big-pharma firm that saw the future
Long ago Roche bet on personalised health care. Now its time has come
ROCHE IS A strange entity. The Swiss giant is the world’s second-biggest drugmaker and one of big pharma’s most profitable firms. But its largest shareholding group, mostly descended from Fritz Hoffmann-La Roche, who founded the company in 1896, is led by André Hoffmann, a nature lover and sustainability advocate who believes that the purpose of business is not mainly to make money. Even its bosses are discouraged from making a quick franc. Severin Schwan, an Austrian who has led the company since 2008, is only Roche’s seventh CEO in 125 years. Much of his pay is tied up in company stock for ten years, giving him, as he puts it, “literally a vested interest” in its long-term future.
This article appeared in the Business section of the print edition under the headline “The firm that saw the future”
More from Business
Corporate America’s diversity wars are just getting started
Donald Trump’s attacks on DEI are causing huge headaches for bosses
What Elon Musk should learn from Larry Ellison
The founder of Oracle has demonstrated remarkable staying power
Football clubs are making more money than ever. Players not so much
For both teams and their top stars, it helps to have a brand
The allure of the company town
Lego, Corning and the survival of an old idea
From cribs to carriers, high-end baby products are in vogue
Demographic and technological changes are making infancy more expensive
No one gains from American tariffs on cars from Mexico and Canada
Donald Trump’s levy will hit his country’s carmakers hardest